港股百奥赛图盈喜后早盘一度涨超40%，预计全年营收增长约40%，纯利增长约400%

Core Viewpoint - The company BaiAoSaiTu forecasts a significant increase in revenue and net profit for the fiscal year 2025, driven by overseas market expansion and recovery in the domestic biopharmaceutical industry [2] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan, representing an increase of 389 million to 408 million yuan compared to the previous year, with a year-on-year growth rate of 39.61% to 41.65% [2] - The projected net profit attributable to shareholders is around 162 million to 182 million yuan, reflecting an increase of 129 million to 149 million yuan year-on-year, with a substantial growth rate of 384.26% to 443.88% [2] Market Factors - The revenue growth is attributed to the continuous expansion in overseas markets and the recovery of the domestic biopharmaceutical sector [2] - The company maintains a high gross margin due to its strong technical advantages, which are further supported by lean management initiatives that enhance operational efficiency [2]